EP1565486A2 - Procede de preparation de l'acetate de glatiramer par le polymerisation d'un anhydride n-carboxy de la l-alanine, l-tyrosine, l-glutamate benzolique et l-lysine benzoloxycarbonyl - Google Patents
Procede de preparation de l'acetate de glatiramer par le polymerisation d'un anhydride n-carboxy de la l-alanine, l-tyrosine, l-glutamate benzolique et l-lysine benzoloxycarbonylInfo
- Publication number
- EP1565486A2 EP1565486A2 EP03775017A EP03775017A EP1565486A2 EP 1565486 A2 EP1565486 A2 EP 1565486A2 EP 03775017 A EP03775017 A EP 03775017A EP 03775017 A EP03775017 A EP 03775017A EP 1565486 A2 EP1565486 A2 EP 1565486A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- protected
- carried out
- lysine
- group
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 76
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title claims abstract description 33
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims description 23
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims description 23
- 229960003776 glatiramer acetate Drugs 0.000 title claims description 23
- OJTJKAUNOLVMDX-LBPRGKRZSA-N (2s)-6-amino-2-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 OJTJKAUNOLVMDX-LBPRGKRZSA-N 0.000 title 1
- HFZKKJHBHCZXTQ-JTQLQIEISA-N (4s)-4-azaniumyl-5-oxo-5-phenylmethoxypentanoate Chemical compound OC(=O)CC[C@H](N)C(=O)OCC1=CC=CC=C1 HFZKKJHBHCZXTQ-JTQLQIEISA-N 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims abstract description 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 59
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 59
- 229920001577 copolymer Polymers 0.000 claims abstract description 39
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 32
- 238000010511 deprotection reaction Methods 0.000 claims abstract description 30
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 229960003767 alanine Drugs 0.000 claims abstract description 19
- 229960004441 tyrosine Drugs 0.000 claims abstract description 17
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 15
- 238000000746 purification Methods 0.000 claims abstract description 15
- 239000004472 Lysine Substances 0.000 claims abstract description 13
- 235000019766 L-Lysine Nutrition 0.000 claims abstract description 12
- 229930195714 L-glutamate Natural products 0.000 claims abstract description 12
- 150000001413 amino acids Chemical group 0.000 claims abstract description 10
- 229960002989 glutamic acid Drugs 0.000 claims abstract description 10
- 238000000926 separation method Methods 0.000 claims abstract description 10
- 229960003646 lysine Drugs 0.000 claims abstract description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 83
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 238000000502 dialysis Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 230000003197 catalytic effect Effects 0.000 claims description 16
- 238000009901 transfer hydrogenation reaction Methods 0.000 claims description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 11
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 11
- 125000006239 protecting group Chemical group 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- JVEUTCWLEJSEDI-PXYINDEMSA-N (2s)-2,6-diamino-7-oxo-7-phenylmethoxyheptanoic acid Chemical compound OC(=O)[C@@H](N)CCCC(N)C(=O)OCC1=CC=CC=C1 JVEUTCWLEJSEDI-PXYINDEMSA-N 0.000 claims description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- 239000003999 initiator Substances 0.000 claims description 7
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 7
- BGGHCRNCRWQABU-SNVBAGLBSA-N (2r)-2-azaniumyl-5-oxo-5-phenylmethoxypentanoate Chemical class [O-]C(=O)[C@H]([NH3+])CCC(=O)OCC1=CC=CC=C1 BGGHCRNCRWQABU-SNVBAGLBSA-N 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- UVJHQYIOXKWHFD-UHFFFAOYSA-N cyclohexa-1,4-diene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 5
- 229940024606 amino acid Drugs 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 5
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004280 Sodium formate Substances 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims description 4
- 235000019254 sodium formate Nutrition 0.000 claims description 4
- 229940043279 diisopropylamine Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000005208 trialkylammonium group Chemical group 0.000 claims description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 159000000021 acetate salts Chemical class 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 238000010549 co-Evaporation Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- -1 CH2C12 Chemical compound 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- NGXZRXLIUBALRQ-AKGZTFGVSA-N (2s)-2,6-diamino-8,8,8-trifluoro-7-oxooctanoic acid Chemical compound OC(=O)[C@@H](N)CCCC(N)C(=O)C(F)(F)F NGXZRXLIUBALRQ-AKGZTFGVSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013628 high molecular weight specie Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940124364 agent for multiple sclerosis Drugs 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Definitions
- Glatiramer Acetate is a synthetic polypeptide analog of myelin basic protein (MBP), which is a natural component of the myelin sheath. It is also defined in the Physicians' Desk Reference, 56 th Edition 2002 as consisting of acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: namely, L- glutamic acid, L-alanine, L-tyrosine and L-lysine with an average molar fraction of 0.141, 0.427, 0.095 and 0.338 respectively. The average molecular weight is 4,700- 11,000 daltons.
- Glatiramer Acetate is a novel, safe and effective treatment for patients with the exacerbating- remitting form of multiple sclerosis and it is the active ingredient of CopaxoneTM, a medicament used for the treatment of multiple sclerosis.
- the process for the synthesis of Glatiramer Acetate is based on the polymerization of N-carboxyanhydrides of alanine 2, ⁇ -benzyl glutamate 3, N ⁇ -trifluoroacetyl lysine 7 and tyrosine 5, in anhydrous and cancer suspect solvent dioxane at room temperature for 24 hours using diethylamine as initiator (Scheme 2).
- Glatiramer acetate with the required average molecular weight (4.7 to 11 kDa) can be obtained either by chromatography of intermediate 10 containing high molecular weight species and collecting the fractions without the undesired species or by partial acid or enzymatic hydrolysis to remove the high molecular weight species with subsequent purification by dialysis or ultrafiltration. Further methods to obtain Glatiramer Acetate having the required average molecular weight are based on the preparation of the desired species while the amino acids are still protected, followed by deprotection.
- the present invention is directed to a new process for the preparation of a polypeptide designated in the present invention as 1 comprising the following amino acid units in the structure, namely: L-alanine, L-glutamic acid, L- lysine and L-tyrosine randomly arranged in the polypeptide 1, or a pharmaceutically acceptable salt thereof wherein said process, comprises the steps of:
- the advantages of the current process are the result of (i) the novel choice of side chain protection on the glutamic acid and lysine moieties and (ii) the utilization of acetic acid as solvent for the deprotection step thereby permitting the isolation of polypeptide 1 as an acetate salt directly from the reaction mixture without any additional procedures.
- said polymerization is carried out in the presence of an initiator, preferably said initiator comprises at least one of the following: diethylamine, triethylamine and diisopropylamine.
- a process of manufacturing Glatiramer Acetate comprising a single step deprotection of a protected copolymer 6, said protected copolymer 6 comprising a mixture of L- alanine, L-tyrosine, a protected L-glutamate and a protected L-lysine, protected by at least one protecting group, preferably said at least one protecting group is selected from a substituted or unsubstituted ⁇ -benzyl group or a substituted or unsubstituted N ⁇ -benzyloxycarbonyl group or an aryl group, preferably said substituted ⁇ -benzyl group or N ⁇ -benzyloxycarbonyl group is substituted with at least one of the following: Br, CI, NO 2 , OCH 3 .
- said separation and purification of the polypeptide 1 is carried out in a single step, preferably said single step involves a single dialysis against water.
- Protected Copolymer 6 (2.00 g) was dissolved in 40 mL of acetic acid by heating at 80°C under nitrogen. To the yellow solution was added 0.6 g Pd/C (30% wt.) and cyclohexene (5 mL) and then the reaction mixture was stirred at 80°C under nitrogen for 4 hours. The reaction was filtered through celite and the cake was washed with 4 mL of hot acetic acid. After evaporation of the filtrate with 32 mL toluene, a beige solid was obtained (polypeptide 1, 1.4 g, 70%).
- Protected copolymer 6 (5.00 g) was dissolved in 100 mL of acetic acid by heating at 80°C under nitrogen. To the yellow solution was added 1.5 g Pd/C (30% wt.) and 1,4-cyclohexadiene (7.4 mL) and then the reaction mixture was stirred at 80 0 C under nitrogen for 48 hours. The reaction was filtered through celite and the cake washed with 20 mL of hot acetic acid. After evaporation of the filtrate with 32 mL toluene, a beige solid was obtained (polypeptide 1, 2.8 g, 56%).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Polyamides (AREA)
Abstract
L'invention concerne un procédé de préparation d'un polypeptide désigné dans l'invention comme 1, constitué, dans la structure, des unités d'acides aminés suivantes: L-alanine, acide L-glutamique, L-lysine et L-tyrosine agencés aléatoirement dans le polypeptide 1, ou dans des sels pharmaceutiquement acceptables de ce polypeptide. Ledit procédé consiste : a) à polymériser un mélange de N-carboxyanhydrides de L-alanine, L-tyrosine, L-glutamate protégé et L-lysine protégé afin d'obtenir un copolymère 6 protégé ou un sel de ce copolymère (formule (I)) ; b) à déprotéger le copolymère 6 (ou un sel de ce copolymère) afin de produire le polypeptide 1 ou un sel pharmaceutiquement acceptable de celui-ci en une seule étape (formule (II)) ; c) à séparer et à purifier le polypeptide 1 (ou un sel pharmaceutiquement acceptable de celui-ci) afin d'obtenir un polypeptide 1 purifié. (formule (III)).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002411786A CA2411786C (fr) | 2002-11-13 | 2002-11-13 | Methode de preparation de polypeptide 1 |
| CA2411786 | 2002-11-13 | ||
| US10/326,994 US7049399B2 (en) | 2002-11-13 | 2002-12-24 | Process for the preparation of polypeptide 1 |
| US326994 | 2002-12-24 | ||
| PCT/CA2003/001744 WO2004043995A2 (fr) | 2002-11-13 | 2003-11-13 | Procede de preparation de polypeptide 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1565486A2 true EP1565486A2 (fr) | 2005-08-24 |
Family
ID=32313425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03775017A Withdrawn EP1565486A2 (fr) | 2002-11-13 | 2003-11-13 | Procede de preparation de l'acetate de glatiramer par le polymerisation d'un anhydride n-carboxy de la l-alanine, l-tyrosine, l-glutamate benzolique et l-lysine benzoloxycarbonyl |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1565486A2 (fr) |
| AU (1) | AU2003283152A1 (fr) |
| WO (1) | WO2004043995A2 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2469393C (fr) | 2001-12-04 | 2010-05-25 | Teva Pharmaceutical Industries, Ltd. | Procedes pour mesurer la puissance de l'acetate de glatiramer |
| NZ554018A (en) * | 2004-09-09 | 2009-06-26 | Teva Pharma | Process for preparation of trifluoroacetyl glatiramer acetate using purified hydrobromic acid |
| DK1797109T3 (en) * | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| WO2006050122A1 (fr) | 2004-10-29 | 2006-05-11 | Sandoz Ag | Procedes de preparation d'un glatiramere |
| US20060172942A1 (en) * | 2005-02-02 | 2006-08-03 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
| ES2338488T3 (es) * | 2006-07-05 | 2010-05-07 | Momenta Pharmaceuticals, Inc. | Proceso mejorado para la preparacion de copolimero-1. |
| US8753833B2 (en) | 2007-06-21 | 2014-06-17 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
| US8993722B2 (en) | 2007-07-31 | 2015-03-31 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
| WO2009129018A1 (fr) | 2008-04-16 | 2009-10-22 | Momenta Pharmaceuticals, Inc. | Analyse de compositions copolymères d'acides aminés |
| SG10201405806SA (en) | 2009-08-20 | 2014-11-27 | Yeda Res & Dev | Low Frequency Glatiramer Acetate Therapy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| WO2013009885A2 (fr) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation de diéthylamide de copolymère |
| AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| BR112019017724A2 (pt) | 2017-03-26 | 2020-03-31 | Mapi Pharma Ltd. | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
-
2003
- 2003-11-13 EP EP03775017A patent/EP1565486A2/fr not_active Withdrawn
- 2003-11-13 WO PCT/CA2003/001744 patent/WO2004043995A2/fr not_active Ceased
- 2003-11-13 AU AU2003283152A patent/AU2003283152A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2004043995A3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004043995A3 (fr) | 2004-10-07 |
| AU2003283152A8 (en) | 2004-06-03 |
| WO2004043995A2 (fr) | 2004-05-27 |
| AU2003283152A1 (en) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2411786C (fr) | Methode de preparation de polypeptide 1 | |
| WO2004043995A2 (fr) | Procede de preparation de polypeptide 1 | |
| US8212002B2 (en) | Synthesis of glatiramer acetate | |
| Overberger et al. | Graft copolymers containing nucleic acid bases and L‐α‐amino acids | |
| KR20070108388A (ko) | 가수소분해를 이용한 폴리펩타이드의 혼합물의 제조방법 | |
| CA2827275A1 (fr) | Copolymere-1, son procede de preparation et methodes d'analyse de celui-ci | |
| EP0142231A1 (fr) | Procédé de préparation de résine de polyaminoacides séquencées | |
| JPS611700A (ja) | 免疫系に対する作用を有するペンタペプチドの製造方法およびこの方法のための中間体 | |
| DK170649B1 (da) | Corticotropinderivater og fysiologisk acceptable salte deraf, deres fremstilling og lægemidler, der indeholder dem | |
| NZ197294A (en) | Peptides | |
| JPS63250360A (ja) | サイモペンチンレトロ−インバーソ類似体及びそのフラグメント | |
| Mathias et al. | Polydepsipeptides. 6. Synthesis of sequential polymers containing varying ratios of L-alanine and L-lactic acid | |
| IE903851A1 (en) | Iodothyronine polymers | |
| WO2009017775A2 (fr) | Procédé de préparation d'un polypeptide | |
| SU1182051A1 (ru) | Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина | |
| AU2011248663A1 (en) | Preparation of polypeptides and salts thereof | |
| Trudelle | Sequential polypeptides. Synthesis of poly-(L-tyrosyl-L-glutamyl-L-tyrosyl-L-glutamyl), poly-(L-glutamyl-L-tyrosyl-L-glutamyl), and poly-(L-glutamyl-L-glutamyl-L-tyrosyl-L-glutamyl) by use of catechol esters | |
| HU202553B (en) | Process for producing isopolypeptides composed of diamino monokarboxylic acids and pharmaceutical compositions comprising same, as well as plant protective comprising polyisolysine | |
| US4525576A (en) | Process for producing sequential polyamino acid resin | |
| CN1300293A (zh) | 四肽的制备方法 | |
| GB2478837A (en) | Preparation of glatiramer | |
| Plöger et al. | Improved Large‐Scale Liquid‐Phase Synthesis and High‐Temperature NMR Characterization of Short (F‐) PNAs | |
| JP2617700B2 (ja) | 細胞接着活性コア配列の繰り返し構造からなるポリペプチド | |
| JPH0741467A (ja) | 新規ｎ−カルボキシアミノ酸無水物 | |
| JP2014532692A (ja) | ランダムポリペプチドの調製プロセス、及び、酢酸ガラティラメルを製造するためのガイダンスツールとして円偏光二色性を用いること |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20050513 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20081212 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20121207 |